Azvudine reduces COVID-19 risk: real-time meta analysis of 39 studies (Version 40)

Significantly lower risk is seen for mortality, ICU admission, hospitalization, progression, and viral clearance. 30 studies from 22 independent teams in 2 countries show significant benefit.

Meta analysis using the most serious outcome reported shows 26% [18‑33%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and peer-reviewed studies.

Results are very robust — in exclusion sensitivity analysis 20 of 39 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.

Control Azvudine

Studies show significantly increased risk of liver injury1,2.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.

5 other meta analyses show significant improvements with azvudine for mortality3-7, mechanical ventilation3, clinical improvement3, progression7, and viral clearance3,5,6.

5 meta analyses show significant improvements with azvudine for mortality1-5, mechanical ventilation1, improvement1, progression5, and viral clearance1,3,4.